TG Therapeutics Expects Q1 BRIUMVI U.S. Net Product Revenue Of $41M - $46M; FY24 Revenue Of $220M - $260M
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics projects Q1 BRIUMVI U.S. net product revenue to be between $41M and $46M. For FY24, the company anticipates revenue to range from $220M to $260M.
January 10, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics expects a significant increase in Q1 BRIUMVI U.S. net product revenue and a substantial revenue forecast for FY24.
The positive revenue projections for both Q1 and FY24 suggest strong sales performance and growth potential for TG Therapeutics, which could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100